Eli Lilly reported Q3 2026 Mounjaro revenue of $10.7 billion, up 65% year-over-year, exceeding consensus estimates near $10.1 billion as worldwide volume rose 53% and offset a 15% decline in realized prices. U.S. sales grew 41% to $5.0 billion on sustained demand, while international revenue surged 93% to $5.7 billion, supported by expanded access including China's NRDL listing that boosted volume despite lower prices. The tirzepatide franchise (Mounjaro and Zepbound) drove the bulk of Lilly's $24.4 billion total revenue, prompting the company to raise full-year 2026 revenue guidance to $91–92 billion. Traders monitoring resolution thresholds will focus on these volume trends versus ongoing pricing dynamics and any last-minute adjustments to rebate estimates ahead of final figures.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated1H6H1D7D30DALL
View resolved

Beware of external links.
Beware of external links.
Frequently Asked Questions